Severe Decrease in Serum HDL-Cholesterol During Combination Therapy of Bezafibrate and Pioglitazone-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Severe Decrease in Serum HDL-Cholesterol During Combination Therapy of Bezafibrate and Pioglitazone

Published:2006 Issue:5 Volume:13 Page:263-264
ISSN:1880-3873
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Senba Hiroaki,Kawano Mikihiko,Kawakami Masanobu

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/13/5/13_5_263/_pdf

Reference4 articles.

1. 1) Ebcioglu Z, Morgan J, Carey C, and Capuzzi D: Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med, 2003; 139: W80

2. Severe Hypo-α-Lipoproteinemia During Treatment With Rosiglitazone

3. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

4. The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interaction Between Peroxisome Proliferator Activated Receptor δ and Epithelial Membrane Protein 2 Polymorphisms Influences HDL-C Levels in the Chinese Population;Annals of Human Genetics;2016-08-17

2. Fibrates;Clinical Lipidology;2015

3. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin;Lipids in Health and Disease;2011

4. Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes;Arquivos Brasileiros de Endocrinologia & Metabologia;2010-10

5. Paradoxical Severe Decrease in High-Density Lipoprotein Cholesterol Due to Rosiglitazone-Fenofibrate Interaction;Endocrine Practice;2010-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3